<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="39350"><DrugName>pridopidine</DrugName><DrugNamesKey><Name id="42923780">Huntexil</Name><Name id="42912034">pridopidine</Name><Name id="42927497">pridopidine hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>ACR-16, Teva</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>dopamine modulator (neurological disorders), Merck &amp; Co</Value></Name><Name><Value>dopamine modulator (Huntingtons disease), Carlsson Research</Value></Name><Name><Value>dopamine modulator (schizophrenia), Fujisawa</Value></Name><Name><Value>dopamine modulator (schizophrenia), Astellas</Value></Name><Name><Value>dopamine modulator (Huntingtons disease), NeuroSearch</Value></Name><Name><Value>ASP-2314</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>pridopidine</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>Huntexil</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>pridopidine hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>TV-7820</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>346688-38-8</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>882737-42-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="28878">A Carlsson Research AB</CompanyOriginator><CompaniesSecondary><Company id="1013295">Astellas Pharma Inc</Company><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Company id="18077">Merck &amp; Co Inc</Company><Company id="18504">NeuroSearch A/S</Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Company id="28878">A Carlsson Research AB</Company></CompaniesSecondary><CrossReferences><SourceEntity id="39350" type="Drug"><TargetEntity id="318494" type="siDrug">Pridopidine</TargetEntity></SourceEntity><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="16227" type="Company"><TargetEntity id="4295876872" type="organizationId">Fujisawa Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="18504" type="Company"><TargetEntity id="4295866025" type="organizationId">Neurosearch A/S</TargetEntity></SourceEntity><SourceEntity id="20348" type="Company"><TargetEntity id="4295875158" type="organizationId">Teva Pharmaceutical Industries Ltd</TargetEntity></SourceEntity><SourceEntity id="28878" type="Company"><TargetEntity id="5035561373" type="organizationId">A Carlsson Research AB</TargetEntity></SourceEntity><SourceEntity id="170" type="ciIndication"><TargetEntity id="G10" type="ICD10"></TargetEntity><TargetEntity id="10020469" type="MEDDRA"></TargetEntity><TargetEntity id="D006816" type="MeSH"></TargetEntity><TargetEntity id="399" type="ORPHANET"></TargetEntity><TargetEntity id="-682751376" type="omicsDisease"></TargetEntity><TargetEntity id="126" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="255" type="ciIndication"><TargetEntity id="G20" type="ICD10"></TargetEntity><TargetEntity id="10061536" type="MEDDRA"></TargetEntity><TargetEntity id="D010300" type="MeSH"></TargetEntity><TargetEntity id="-342157116" type="omicsDisease"></TargetEntity><TargetEntity id="127" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"></TargetEntity><TargetEntity id="10039626" type="MEDDRA"></TargetEntity><TargetEntity id="D012559" type="MeSH"></TargetEntity><TargetEntity id="-729613619" type="omicsDisease"></TargetEntity><TargetEntity id="65" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="34" type="ciIndication"><TargetEntity id="F90" type="ICD10"></TargetEntity><TargetEntity id="10003736" type="MEDDRA"></TargetEntity><TargetEntity id="D001289" type="MeSH"></TargetEntity><TargetEntity id="-197354408" type="omicsDisease"></TargetEntity><TargetEntity id="87" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="368" type="ciIndication"><TargetEntity id="10028035" type="MEDDRA"></TargetEntity><TargetEntity id="D009069" type="MeSH"></TargetEntity><TargetEntity id="-1499226996" type="omicsDisease"></TargetEntity><TargetEntity id="132" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="60" type="ciIndication"><TargetEntity id="D002493" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="90" type="ciIndication"><TargetEntity id="10012267" type="MEDDRA"></TargetEntity><TargetEntity id="D003704" type="MeSH"></TargetEntity><TargetEntity id="-1720562635" type="omicsDisease"></TargetEntity><TargetEntity id="100" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="7948" type="Action"><TargetEntity id="2752" type="Mechanism">sigma1 Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="150" type="Action"><TargetEntity id="125" type="Mechanism">Dopamine D2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00633" type="ciTarget"><TargetEntity id="80088336218133" type="siTarget">D(2) dopamine receptor</TargetEntity><TargetEntity id="8168" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01738" type="ciTarget"><TargetEntity id="33983861102803" type="siTarget">Sigma non-opioid intracellular receptor 1</TargetEntity><TargetEntity id="-1627051158" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="170">Huntingtons chorea</Indication><Indication id="255">Parkinsons disease</Indication><Indication id="299">Schizophrenia</Indication><Indication id="34">Attention deficit hyperactivity disorder</Indication><Indication id="368">Movement disorder</Indication><Indication id="60">Central nervous system disease</Indication><Indication id="90">Dementia</Indication></IndicationsSecondary><ActionsPrimary><Action id="7948">Opioid receptor sigma agonist 1</Action><Action id="16443">BDNF gene modulator</Action><Action id="150">Dopamine D2 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2943">Antipsychotic</Action><Action id="2947">Antiparkinsonian</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="586">Capsule formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>N</Code><Name>CENTRAL NERVOUS SYSTEM</Name></Ephmra><Ephmra><Code>N3A</Code><Name>ANTI-EPILEPTICS</Name></Ephmra><Ephmra><Code>N5A</Code><Name>ANTIPSYCHOTICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-05-17T14:23:02.000Z</LastModificationDate><ChangeDateLast>2018-05-22T00:00:00.000Z</ChangeDateLast><AddedDate>2002-04-22T10:42:09.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="20348" linkType="Company"&gt;Teva Pharmaceutical Industries&lt;/ulink&gt;, following an asset acquisition from &lt;ulink linkID="18504" linkType="Company"&gt;NeuroSearch&lt;/ulink&gt;, was developing pridopidine (ACR-16; Huntexil), a fast-off dopamine D2 receptor antagonist  that strengthens glutamate function and a sigma 1 receptor agonist that acts to increase production of BDNF, for the potential treatment of Huntington's disease (HD) [&lt;ulink linkID="679164" linkType="Reference"&gt;679164&lt;/ulink&gt;], [&lt;ulink linkID="679165" linkType="Reference"&gt;679165&lt;/ulink&gt;], [&lt;ulink linkID="734011" linkType="Reference"&gt;734011&lt;/ulink&gt;], [&lt;ulink linkID="1004646" linkType="Reference"&gt;1004646&lt;/ulink&gt;], [&lt;ulink linkID="1032348" linkType="Reference"&gt;1032348&lt;/ulink&gt;], [&lt;ulink linkID="1036809" linkType="Reference"&gt;1036809&lt;/ulink&gt;], [&lt;ulink linkID="1327033" linkType="Reference"&gt;1327033&lt;/ulink&gt;],  [&lt;ulink linkID="1797440" linkType="Reference"&gt;1797440&lt;/ulink&gt;]. However, in April 2018, Teva discontinued development of pridopidine as it did not  meet its primary endpoints in a phase II trial for HD [&lt;ulink linkID="2025494" linkType="Reference"&gt;2025494&lt;/ulink&gt;], [&lt;ulink linkID="2035016" linkType="Reference"&gt;2035016&lt;/ulink&gt;]. In May 2018, Teva was seeking to sell the drug; at that time, an undisclosed company had shown a potential interest in pridopidine [&lt;ulink linkID="2035016" linkType="Reference"&gt;2035016&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, a European phase  III HD study began  [&lt;ulink linkID="900077" linkType="Reference"&gt;900077&lt;/ulink&gt;];   positive topline data were reported in February 2010 [&lt;ulink linkID="1074612" linkType="Reference"&gt;1074612&lt;/ulink&gt;], but in April 2010, the data were reanalyzed and it was reported that the primary endpoint of the study was not met [&lt;ulink linkID="1094608" linkType="Reference"&gt;1094608&lt;/ulink&gt;]. In March 2011, the FDA concluded that further clinical data would be needed to support an NDA submission [&lt;ulink linkID="1179054" linkType="Reference"&gt;1179054&lt;/ulink&gt;]. In March 2014, a further phase II trial in HD was initiated  [&lt;ulink linkID="1550294" linkType="Reference"&gt;1550294&lt;/ulink&gt;]; mixed data were reported in September 2016 [&lt;ulink linkID="1797440" linkType="Reference"&gt;1797440&lt;/ulink&gt;]. In September 2015, another phase II trial was initiated [&lt;ulink linkID="1975096" linkType="Reference"&gt;1975096&lt;/ulink&gt;]. In February 2017, a phase III trial was expected to begin that year, with the company noting it had additional insights on the drug's mechanism of action [&lt;ulink linkID="1900912" linkType="Reference"&gt;1900912&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1013295" linkType="Company"&gt;Astellas&lt;/ulink&gt; (formerly &lt;ulink linkID="16227" linkType="Company"&gt;Fujisawa Pharmaceutical&lt;/ulink&gt;) was previously developing &lt;ulink linkID="39350" linkType="Drug"&gt;&lt;/ulink&gt;the drug for the potential treatment of schizophrenia [&lt;ulink linkID="584168" linkType="Reference"&gt;584168&lt;/ulink&gt;], [&lt;ulink linkID="927056" linkType="Reference"&gt;927056&lt;/ulink&gt;]. By October 2006, Astellas had initiated a phase I schizophrenia  trial in Japan [&lt;ulink linkID="734011" linkType="Reference"&gt;734011&lt;/ulink&gt;]; in April 2007, the company began a phase Ib schizophrenia study in the US [&lt;ulink linkID="782327" linkType="Reference"&gt;782327&lt;/ulink&gt;]. In May 2008, phase I schizophrenia trials were ongoing [&lt;ulink linkID="927056" linkType="Reference"&gt;927056&lt;/ulink&gt;]. However, in March 2009, it was announced that Astellas had returned all rights to the drug to NeuroSearch as part of a   strategic assessment [&lt;ulink linkID="988569" linkType="Reference"&gt;988569&lt;/ulink&gt;]. Carlsson was also previously developing the drug for Parkinson's disease (PD)-associated dyskinesia and schizophrenia, and was investigating pridopidine for ADHD, late-stage Parkinson's disease  and dementia [&lt;ulink linkID="448659" linkType="reference"&gt;448659&lt;/ulink&gt;], [&lt;ulink linkID="469323" linkType="reference"&gt;469323&lt;/ulink&gt;], [&lt;ulink linkID="518452" linkType="reference"&gt;518452&lt;/ulink&gt;].  By April 2002, the first phase I study had been completed [&lt;ulink linkID="448659" linkType="reference"&gt;448659&lt;/ulink&gt;]. By November 2002, pridopidine was in phase Ib trials in patients with PD dyskinesia and schizophrenia [&lt;ulink linkID="469323" linkType="reference"&gt;469323&lt;/ulink&gt;]. However, in March 2003, pridopidine was licensed to &lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt; [&lt;ulink linkID="518452" linkType="Reference"&gt;518452&lt;/ulink&gt;]; the alliance was terminated in late 2003  [&lt;ulink linkID="679166" linkType="Reference"&gt;679166&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Teva holds worldwide patents relating to pridopidine (&lt;ulink linkID="PA2992591" linkType="Patent"&gt;US-06903120&lt;/ulink&gt;), with expiry in December 2020 [&lt;ulink linkID="1900912" linkType="Reference"&gt;1900912&lt;/ulink&gt;]; in February 2018, Teva stated that the patents had the potential for extension in various markets [&lt;ulink linkID="2005038" linkType="Reference"&gt;2005038&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In August 2009, NeuroSearch planned to make the drug available on a compassionate use basis to patients completing the MermaiHD and HART studies. At that time, the company expected to file for approval in 2010 [&lt;ulink linkID="1037145" linkType="Reference"&gt;1037145&lt;/ulink&gt;]; by August 2010, the compassionate use program had been established in all eight of the European countries where the MermaiHD study had been conducted and the company was working on providing  access to the drug to patients in the US and Canada, who had completed the HART study. At that time, the company planned to discuss marketing approval strategies with European and US regulatory authorities once results from the MermaiHD and HART studies were available [&lt;ulink linkID="1126262" linkType="Reference"&gt;1126262&lt;/ulink&gt;]. In March 2011, Neurosearch received preliminary feedback from an end-of-phase II meeting with the FDA, indicating that further clinical data would be needed to support an NDA submission [&lt;ulink linkID="1179054" linkType="Reference"&gt;1179054&lt;/ulink&gt;]; in May 2011, NeuroSearch received feedback from the EMA  indicating that a new confirmatory phase III study  would be needed to support an MAA   [&lt;ulink linkID="1194378" linkType="Reference"&gt;1194378&lt;/ulink&gt;]. The new phase III program would have the total motor score (TMS), as its primary endpoint [&lt;ulink linkID="1206146" linkType="Reference"&gt;1206146&lt;/ulink&gt;]. In February 2017, a phase III trial was expected to begin that year [&lt;ulink linkID="1900912" linkType="Reference"&gt;1900912&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2005, pridopidine received EU Orphan Drug designation for HD [&lt;ulink linkID="679164" linkType="Reference"&gt;679164&lt;/ulink&gt;]. In January 2006, it received FDA Orphan Drug status for this indication [&lt;ulink linkID="679163" linkType="Reference"&gt;679163&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Huntington's disease&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In February 2017, a phase III trial was expected to begin that year [&lt;ulink linkID="1900912" linkType="Reference"&gt;1900912&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2011, the company was planning the 26-week, phase III, randomized, double-blind, placebo-controlled,  Prime-HD study which would enroll 630 patients in the US and Europe and possibly also in South America and Australia. Dosing was expected to start in 1H12 [&lt;ulink linkID="1226055" linkType="Reference"&gt;1226055&lt;/ulink&gt;]. The company would submit a phase III study protocol to the FDA  during 4Q11 for informal protocol review  and then finalize the details of the Prime-HD study [&lt;ulink linkID="1251585" linkType="Reference"&gt;1251585&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, NeuroSearch held a pre-IND meeting with the FDA to allow it to begin clinical development of the drug in the US for HD [&lt;ulink linkID="804562" linkType="Reference"&gt;804562&lt;/ulink&gt;]. The company filed a CTA to begin a European phase III trial in October 2007. At that time, a 3-month US study was also planned. The 6-month, multicenter, randomized, double-blind, placebo-controlled European study would test 45 or 90 mg/day of the drug in 420 patients. The primary endpoint was the change in the modified motor score subscale of the unified HD rating scale. Secondary objectives were overall improvement, behavior, depression and anxiety, cognitive function, safety and tolerability [&lt;ulink linkID="835471" linkType="Reference"&gt;835471&lt;/ulink&gt;]. The phase III MermaiHD (Multinational European Multicentre ACR16 study in Huntington's Disease) trial (&lt;ulink linkID="11649" linkType="Protocol"&gt;NCT00665223&lt;/ulink&gt;;  ACR16; C008) began in Europe in April 2008. At that time, the study was scheduled to complete in June 2009 [&lt;ulink linkID="900196" linkType="Reference"&gt;900196&lt;/ulink&gt;],  [&lt;ulink linkID="900077" linkType="Reference"&gt;900077&lt;/ulink&gt;]. In March 2009, NeuroSearch reported that enrollment in the trial had been completed with 437 patients recruited. At that time, 80 patients had completed 26 weeks of treatment and had chosen to continue in a 6-month, open-label extension of the study. A positive safety profile had so far  been demonstrated [&lt;ulink linkID="997021" linkType="Reference"&gt;997021&lt;/ulink&gt;], [&lt;ulink linkID="1057419" linkType="Reference"&gt;1057419&lt;/ulink&gt;]. In February 2010, topline results were reported. The primary endpoint of improvement in voluntary motor function was achieved. In the intention-to-treat population, there were significant improvements in modified motor score, total motor score, eye movements and dystonia in patients who were treated with pridopidine 45 mg bid for 6 months, compared with placebo. There were some improvements in these symptoms in the pridopidine 45 mg qd group; however, these were not significant. In the pridopidine 45 mg bid group, improvements in motor functions continued to increase over time, compared with placebo. Antipsychotics, which were being taken by approximately 40% of patients, did not interfere with the effects of pridopidine. Pridopidine was tolerated. Nearly 90% of patients had chosen to continue treatment in the open-label extension, which was ongoing [&lt;ulink linkID="1072849" linkType="Reference"&gt;1072849&lt;/ulink&gt;], [&lt;ulink linkID="1074612" linkType="Reference"&gt;1074612&lt;/ulink&gt;], [&lt;ulink linkID="1076466" linkType="Reference"&gt;1076466&lt;/ulink&gt;]. In March 2010, further analysis of the results showed that pridopidine also delayed the progression of the underlying disease, regardless of the patient's disease-genotype [&lt;ulink linkID="1080290" linkType="Reference"&gt;1080290&lt;/ulink&gt;]. However, in April 2010, it was reported that the primary endpoint was not met when data were re-analyzed further with revised statistics; reanalyzing the primary endpoint showed that the significance value for the modified Motor Score (mMS) p value was 0.042, which did not meet the pre-specified significance level of p&amp;lt; 0.025. The revised statistics did not alter any other endpoints. At that time,    the company planned to initiate talks with regulatory authorities based on the data [&lt;ulink linkID="1094608" linkType="Reference"&gt;1094608&lt;/ulink&gt;]. By August 2010, the extension study, which had enrolled 353 patients, was completed [&lt;ulink linkID="1126262" linkType="Reference"&gt;1126262&lt;/ulink&gt;]. In September 2010, results from 305-patient open-label extension study showed the drug was tolerated over 12 months of treatment [&lt;ulink linkID="1131154" linkType="Reference"&gt;1131154&lt;/ulink&gt;]. In November 2011, further results were published [&lt;ulink linkID="1237513" linkType="Reference"&gt;1237513&lt;/ulink&gt;], [&lt;ulink linkID="1237627" linkType="Reference"&gt;1237627&lt;/ulink&gt;]. In May 2012, appropriate additional safety measures were to be implemented in the study [&lt;ulink linkID="1294797" linkType="Reference"&gt;1294797&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II/III&lt;/subtitle&gt;In July 2008, NeuroSearch received FDA approval to begin a phase II/III trial [&lt;ulink linkID="924378" linkType="Reference"&gt;924378&lt;/ulink&gt;]. In November 2008, the randomized, double-blind, placebo-controlled (&lt;ulink linkID="25342" linkType="Protocol"&gt;NCT00724048&lt;/ulink&gt;; ACR16 C009; HART (Huntington's disease ACR16 Randomized Trial)) was initiated in the US and Canada in 227 patients who would receive 10, 22.5 or 45 mg of pridopidine once or twice daily, or placebo. The primary endpoint was voluntary motor function according to the modified motor score. Secondary endpoints included overall clinical impression, cognitive function, and neuropsychiatric symptoms [&lt;ulink linkID="924378" linkType="Reference"&gt;924378&lt;/ulink&gt;], [&lt;ulink linkID="1181573" linkType="Reference"&gt;1181573&lt;/ulink&gt;], [&lt;ulink linkID="956463" linkType="Reference"&gt;956463&lt;/ulink&gt;]. In April 2010, recruitment was completed [&lt;ulink linkID="1094620" linkType="Reference"&gt;1094620&lt;/ulink&gt;]. In October 2010, it was reported that the study failed to meet its primary endpoint.  At 12 weeks, the modified motor score (mMS) improved from baseline by 1.2 points in the pridopidine 45 mg group, which was not significant compared with placebo. A significant improvement of 2.8 points was seen for total motor score (TMS), the secondary endpoint. Dose-response relationships were seen for both mMS and TMS. Pridopidine 45 mg group had significant effects on balance, gait and hand movements and positive trends were seen for eye movements, dystonia and chorea. No significant changes were seen in endpoints for cognition, affective symptoms and generalized function/well-bring [&lt;ulink linkID="1139759" linkType="Reference"&gt;1139759&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In September 2015, a multicenter, open-label, phase II trial (&lt;ulink linkID="234548" linkType="Protocol"&gt;NCT02494778&lt;/ulink&gt;; Open PRIDE-HD; TV7820-CNS-20016; 2015-000904-24) was initiated in the US, Australia, Canada and Europe to assess the safety, efficacy and tolerability of the drug in HD patients (expected n = 650). At that time, the trial was expected to complete in October 2022 [&lt;ulink linkID="1975096" linkType="Reference"&gt;1975096&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In March 2014, a randomized, double-blind, placebo-controlled, parallel-group, dose-finding, global phase II trial (&lt;ulink linkID="163341" linkType="Protocol"&gt;NCT02006472&lt;/ulink&gt;; TV7820-CNS-20002, 2013-001888-23; Pride-HD) was initiated in the US, Canada and Europe in patients (expected n = 400) with Huntington's disease to compare the safety and efficacy of different doses of pridopidine versus placebo. The trial was expected to be completed in March 2015. In April 2014, patient enrollment was initiated [&lt;ulink linkID="1550133" linkType="Reference"&gt;1550133&lt;/ulink&gt;], [&lt;ulink linkID="1550294" linkType="Reference"&gt;1550294&lt;/ulink&gt;]. In September 2016, topline data from the 52-week, dose-ranging trial were presented at the 9th European Huntington Disease Network Plenary Meeting in The Hague,  Netherlands.  There was no difference in Total Motor Score between the treatment groups, although there was a significant effect on the endpoint of disease progression at 52 weeks at certain doses versus placebo.  Evidence of symptomatic impact was seen in a subpopulation with early-stage HD, with improvement in Total Motor Score  and dystonia observed at 26 and 52 weeks [&lt;ulink linkID="1797440" linkType="Reference"&gt;1797440&lt;/ulink&gt;]. In April 2017, further clinical data were presented at the 69th AAN Annual Meeting in Boston, MA. From baseline to week 26, the study did not meet the primary endpoint of change in UHDRS Total Motor Score (UHDRS TMS) when compared with placebo. At weeks 26 and 52, pridopidine treatment (all dose levels) showed improvements in TMS from baseline, but in conjunction with a large placebo effect.  At week 52, pridopidine (45 mg, bid) showed effect on functional decline measured by total functional capacity (0.81, p = 0.003), and this benefit was most evident in the two earliest-stage subpopulations (1.16, p &amp;lt; 0.001) when compared with placebo [&lt;ulink linkID="1920026" linkType="Reference"&gt;1920026&lt;/ulink&gt;]. In June 2017, further data were presented at the 21st International PDMD Congress in Vancouver, Canada. At week 24, total motor score was improved compared to baseline at all doses of pridopidine (primary endpoint) including placebo, but did not reach significance, possibly due to a large, enduring placebo response. At week 52, less functional decline as measured by total functional capacity (TFC) was observed with pridopidine 45 mg bid when compared with placebo (least square means difference: 0.87, p = 0.003). A responder analysis revealed that no deterioration (81 versus 49%; p = 0.003) or improvement (27 versus 12%;  = 0.099) in TFC was observed in a larger proportion of early stage pridopidine 45 mg bid patients compared with placebo  [&lt;ulink linkID="1944460" linkType="Reference"&gt;1944460&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2014, a phase II dose-finding, randomized, parallel-group, double-blind, placebo-controlled study (&lt;ulink linkID="163341" linkType="Protocol"&gt;NCT02006472&lt;/ulink&gt;; TV7820-CNS-20002  2013-001888-23), evaluating the safety and efficacy of pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg twice-daily versus placebo for symptomatic treatment was initiated in patients (expected n = 409) with Huntington's disease in Europe and Australia. At that time, the study was to be completed in August 2016 [&lt;ulink linkID="1767041" linkType="Reference"&gt;1767041&lt;/ulink&gt;]. In August 2016, data from the trial were expected in 3Q16 [&lt;ulink linkID="1786113" linkType="Reference"&gt;1786113&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2010, results were reported from a meta-analysis of data from the HART phase IIb and MermaiHD phase III studies showing that pridopidine significantly improved total motor score by -2.1 points at week 12 and -3.3 points at week 26. Improvements of -0.6 and -1.2 points were seen on the modified motor score at week 12 and 26, respectively [&lt;ulink linkID="1158221" linkType="Reference"&gt;1158221&lt;/ulink&gt;]. Further data from the meta-analysis were presented at the World Congress on Huntington's Disease in Melbourne, Australia, in September 2011. Pridopidine (90 mg daily) improved Unified Huntington's Disease Rating Scale total motor score  relative to placebo at weeks 12 and 26 [&lt;ulink linkID="1226722" linkType="Reference"&gt;1226722&lt;/ulink&gt;]. In June 2015, further data were presented at the 19th International PDMD Congress in San Diego, CA. In patients who received both antipsycotics and antidepressants, the incidence of TEAEs was 66.7, 67.9 and 67.5% in the pridopidine 45 and 90 mg and placebo groups, respectively [&lt;ulink linkID="1677019" linkType="Reference"&gt;1677019&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In November 2010, an open-ended, open-label, phase II trial for patients who had completed the HART study was planned and the first patients were expected to begin treatment in 1Q11 [&lt;ulink linkID="1149129" linkType="Reference"&gt;1149129&lt;/ulink&gt;]; in March 2011, the first patient (expected n = 220) was enrolled in the ex-HART patient, non-randomized, single-group assignment, safety and efficacy OPEN-HART study (&lt;ulink linkID="75204" linkType="Protocol"&gt;NCT01306929&lt;/ulink&gt;; ACR16C015). Primary completion date was expected to be January 2014 [&lt;ulink linkID="1181391" linkType="Reference"&gt;1181391&lt;/ulink&gt;], [&lt;ulink linkID="1181537" linkType="Reference"&gt;1181537&lt;/ulink&gt;]. In June 2017, clinical data were presented at the 21st International PDMD Congress in Vancouver, Canada. Mean change from baseline in TFC at 12, 24 and 36 months for the Open-HART cohort matched to 2CARE was -0.8, -1.3 and -1.9, respectively, and for 2 CARE was -1.4, -2.4 and -2.8, respectively; whereas Open-HART cohort matched to CARE-HD was -0.8, -1.2 and -1.8, respectively. Mean change in TFC at 12, 25 and 30 months for CARE-HD was -0.9, -2.4 and -3.1, respectively. Matched Open-HART cohort showed significantly slower decline when compared with 2 CARE at 24 months (p = 0.02) and CARE-HD at 30 months (p = 0.04) [&lt;ulink linkID="1944427" linkType="Reference"&gt;1944427&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2005, a phase II trial was underway [&lt;ulink linkID="679165" linkType="Reference"&gt;679165&lt;/ulink&gt;]. In May 2006, Carlsson reported results from a placebo-controlled, phase II   study (ACR16C007) in 58 HD patients in Sweden and Norway. Pridopidine  improved motor function, particularly chorea, gait and dysarthria, and reduced akinesia. It also showed efficacy in reducing anxiety and depression and enhanced cognitive function [&lt;ulink linkID="679162" linkType="Reference"&gt;679162&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In March 2017, a phase I trial (&lt;ulink linkID="285029" linkType="Protocol"&gt;NCT03019289&lt;/ulink&gt;; TV7820-IMG-10082; 2016-001757-41) was initiated in Germany to assess  the S1R and D2R receptor occupancy of the drug in the human brain of healthy volunteers and HD patients (expected n = 38). At that time, the trial was expected to complete in January 2018  [&lt;ulink linkID="1975097" linkType="Reference"&gt;1975097&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2009, results from pharmacological studies of pridopidine were presented at the World Congress on Huntingdon's disease in Vancouver showing the drug stabilizes psychomotor activity, so may be able to provide clinical relief of psychomotor symptoms in Huntingdon's disease and other conditions that involve dopaminergic dysfunction [&lt;ulink linkID="1042337" linkType="Reference"&gt;1042337&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In June 2014, clinical data from an open-label study were presented at the 18th International Congress of Parkinson's Disease and Movement Disorders in Stockholm, Sweden. Healthy volunteers (n = 22) with the cytochrome (CYP)2D6-extensive metabolizer genotype received metoprolol (100 mg po) before and after pridopidine (45 mg, bid, for 7 days). Pridopidine was found to be a strong inhibitor of CYP2D6 [&lt;ulink linkID="1575159" linkType="Reference"&gt;1575159&lt;/ulink&gt;]. Further data presented at the meeting showed that in patients with CYP2D6-extensive metabolizer genotype and moderate renal impairment showed increased Cmax and AUC values and reduced plasma clearance values. There was no relationship between renal function and adverse events [&lt;ulink linkID="1575378" linkType="Reference"&gt;1575378&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2011, the company had begun a multiple-ascending dose trial in 36 healthy subjects. The trial was expected to complete in 1Q12. At that time, the company was also planning a further three studies, TQT heart, abuse potential and bioequivalence   [&lt;ulink linkID="1226055" linkType="Reference"&gt;1226055&lt;/ulink&gt;]. In May 2012, data were reported from the randomized, placebo-controlled, double-blind, safety, tolerability and pharmacokinetic study of pridopidine in 36 healthy male and female subjects. The active phase of the study was completed  and MTD was found to be 90 mg bid. The study also  aimed   to investigate a dose of 112.5 mg bid, but due to tolerability issues observed at 90 mg bid, the study was stopped at this dose. There was a dose-dependent QT prolongation that reached a level of clinical concern for both the 67.5 and the 90 mg bid groups compared to placebo. The 45 mg bid dose was well tolerated, even though QT prolongation at this dose level was higher than that observed in previous   studies [&lt;ulink linkID="1294797" linkType="Reference"&gt;1294797&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, Astellas began a phase Ib schizophrenia study of pridopidine in the US. The placebo-controlled, multiple-dose-escalation study would test the safety, tolerability and effect on symptoms (using the PANS (Positive And Negative Symptoms' scale)) of the dopaminergic stabilizer in up to 60 patients [&lt;ulink linkID="782327" linkType="Reference"&gt;782327&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2002, pridopidine was in phase Ib trials in both PD-dyskinesia and schizophrenia patients. These trials were expected to finish in early 2003. Initial observations suggested that the drug had few side effects [&lt;ulink linkID="469323" linkType="Reference"&gt;469323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002, a phase I study was completed in Sweden [&lt;ulink linkID="448659" linkType="Reference"&gt;448659&lt;/ulink&gt;], [&lt;ulink linkID="679168" linkType="Reference"&gt;679168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PRECLINCAL STUDIES&lt;/subtitle&gt;In June 2017, preclinical data were presented at the 21st International PDMD Congress in Vancouver, Canada. In mice with intrastriatal 6-hydroxydopamine lesions, pridopidine (0.3 or 1 mg/kg/day) showed gradual amelioration of PD-like motor deficits in tests of spontaneous rotational and forelimb use [&lt;ulink linkID="1944447" linkType="Reference"&gt;1944447&lt;/ulink&gt;]. Further in vivo data were presented at the same conference. In MPTP-lesioned cynomolgus macaque model of PD, treatment with pridopidine (7 and 20 mg/kg, po) dose-dependently reduced peak-dose dyskinesia (both choreiform and dystonic in nature) up to 76% (20 mg/kg; p &amp;lt; 0.001). At dose of 7 mg/kg, pridopidine was largely ineffective in reducing L-DOPA-induced dyskinesia  [&lt;ulink linkID="1944435" linkType="Reference"&gt;1944435&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, data were presented at the 46th SFN Annual Meeting in San Diego, CA. At 95 months, pridopidine had no effect on motor learning, while at 10 months did not improve motor performance. Motor function anxiety was improved with pridopidine with late treatment [&lt;ulink linkID="1871261" linkType="Reference"&gt;1871261&lt;/ulink&gt;].     &lt;/para&gt;&lt;para&gt; In June 2013, preclinical data were presented at the 17th International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia. Pridopidine protected Huntington's disease cells in vitro and ameliorated motor function in vivo [&lt;ulink linkID="1447802" linkType="Reference"&gt;1447802&lt;/ulink&gt;]. Further results also showed modulation of Huntington's disease neuronal nodes and pathways and a reduction  in dystonia [&lt;ulink linkID="1447801" linkType="Reference"&gt;1447801&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2012, preclinical data were published demonstrating the drug to bind to sigma-1 receptor in low concentrations [&lt;ulink linkID="1266690" linkType="Reference"&gt;1266690&lt;/ulink&gt;], [&lt;ulink linkID="1266447" linkType="Reference"&gt;1266447&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  November 2010, preclinical data were presented at the 40th SFN Meeting in San Diego, CA. In rats, treatment with pridopidine prior to  amphetamine  did not have any effect on increased locomotor activity induced by acute administration of amphetamine. However, treatment with pridopidine prior to amphetamine  blocked sensitization of locomotor activity induced by repeated intermittent administration of amphetamine [&lt;ulink linkID="1145222" linkType="Reference"&gt;1145222&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2009, data were presented at the 4th Huntington's Disease Therapeutics Conference in Cannes, France, showing that pridopidine acted as a dopamine D2 receptor antagonist with fast-off kinetics, and strengthened glutamate function in the frontal cortex [&lt;ulink linkID="1004646" linkType="Reference"&gt;1004646&lt;/ulink&gt;], in July 2010, similar data were published [&lt;ulink linkID="1128230" linkType="Reference"&gt;1128230&lt;/ulink&gt;], [&lt;ulink linkID="1128330" linkType="Reference"&gt;1128330&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2002, preclinical data were presented at the 32nd Neuroscience meeting in Orlando, FL. Pridopidine, prevented L-DOPA-induced sensitization in 6-OHDA-lesioned rats, indicating that concomitant administration of pridopidine and L-DOPA significantly decreased L-DOPA-induced contralateral rotation and asymmetrical behavior, whilst still permitting L-DOPA-induced locomotor activity. Pridopidine may reduce L-DOPA dyskinesia with out reducing L-DOPA's beneficial effects. Initial observations based on undisclosed phase I trial data suggest that the drug is free from side effects [&lt;ulink linkID="469137" linkType="reference"&gt;469137&lt;/ulink&gt;], [&lt;ulink linkID="469323" linkType="reference"&gt;469323&lt;/ulink&gt;]. Pharmacokinetic studies in rats indicated that pridopidine had a Cmax of  30 min post oral administration and an estimated bioavailability of 85% [&lt;ulink linkID="468746" linkType="reference"&gt;468746&lt;/ulink&gt;]. Pridopidine had low affinity, IC50 &amp;gt; 10(5) M, at dopaminergic, serotonergic, noradrenergic and other known neuroreceptors or transmitter-related proteins, as measured by conventional in vitro assays [&lt;ulink linkID="468752" linkType="reference"&gt;468752&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18504">NeuroSearch A/S</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-19T00:00:00.000Z</StatusDate><Source id="2025494" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="368">Movement disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="679166" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-19T00:00:00.000Z</StatusDate><Source id="2025494" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="679166" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18504">NeuroSearch A/S</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-19T00:00:00.000Z</StatusDate><Source id="2025494" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="90">Dementia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="679166" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-19T00:00:00.000Z</StatusDate><Source id="2025494" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="679166" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="255">Parkinsons disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="679166" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18504">NeuroSearch A/S</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-19T00:00:00.000Z</StatusDate><Source id="2025494" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-03-02T00:00:00.000Z</StatusDate><Source id="988569" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-03-02T00:00:00.000Z</StatusDate><Source id="988569" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="34">Attention deficit hyperactivity disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="679166" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-19T00:00:00.000Z</StatusDate><Source id="2025494" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-04-19T00:00:00.000Z</StatusDate><Source id="2025494" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="60">Central nervous system disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="679166" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18504">NeuroSearch A/S</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-04-25T00:00:00.000Z</StatusDate><Source id="900077" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18504">NeuroSearch A/S</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-04-22T00:00:00.000Z</StatusDate><Source id="900196" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18504">NeuroSearch A/S</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-11-03T00:00:00.000Z</StatusDate><Source id="956463" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28878">A Carlsson Research AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-04-22T00:00:00.000Z</StatusDate><Source id="448659" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28878">A Carlsson Research AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="90">Dementia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-04-22T00:00:00.000Z</StatusDate><Source id="448659" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-10T00:00:00.000Z</StatusDate><Source id="518452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="60">Central nervous system disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-10T00:00:00.000Z</StatusDate><Source id="518452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28878">A Carlsson Research AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="255">Parkinsons disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-11-07T00:00:00.000Z</StatusDate><Source id="469323" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28878">A Carlsson Research AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-11-07T00:00:00.000Z</StatusDate><Source id="469323" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-10T00:00:00.000Z</StatusDate><Source id="518452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="255">Parkinsons disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-10T00:00:00.000Z</StatusDate><Source id="518452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="368">Movement disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-10T00:00:00.000Z</StatusDate><Source id="518452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28878">A Carlsson Research AB</Company><Country id="NO">Norway</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-05-23T00:00:00.000Z</StatusDate><Source id="679165" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1767041" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-25T00:00:00.000Z</StatusDate><Source id="1341104" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-25T00:00:00.000Z</StatusDate><Source id="1341104" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-25T00:00:00.000Z</StatusDate><Source id="1341104" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18504">NeuroSearch A/S</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-25T00:00:00.000Z</StatusDate><Source id="1341104" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18504">NeuroSearch A/S</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-25T00:00:00.000Z</StatusDate><Source id="1341104" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18504">NeuroSearch A/S</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-25T00:00:00.000Z</StatusDate><Source id="1341104" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28878">A Carlsson Research AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="368">Movement disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-11-07T00:00:00.000Z</StatusDate><Source id="469323" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28878">A Carlsson Research AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="60">Central nervous system disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-04-22T00:00:00.000Z</StatusDate><Source id="448659" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28878">A Carlsson Research AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="255">Parkinsons disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-04-22T00:00:00.000Z</StatusDate><Source id="448659" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28878">A Carlsson Research AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-04-22T00:00:00.000Z</StatusDate><Source id="448659" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28878">A Carlsson Research AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="34">Attention deficit hyperactivity disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-04-22T00:00:00.000Z</StatusDate><Source id="448659" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="90">Dementia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-10T00:00:00.000Z</StatusDate><Source id="518452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="255">Parkinsons disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-10T00:00:00.000Z</StatusDate><Source id="518452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-10T00:00:00.000Z</StatusDate><Source id="518452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="34">Attention deficit hyperactivity disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-03-10T00:00:00.000Z</StatusDate><Source id="518452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-02-07T00:00:00.000Z</StatusDate><Source id="584168" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-01T00:00:00.000Z</StatusDate><Source id="592748" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28878">A Carlsson Research AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-05-23T00:00:00.000Z</StatusDate><Source id="679165" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18504">NeuroSearch A/S</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-10-23T00:00:00.000Z</StatusDate><Source id="734011" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-10-23T00:00:00.000Z</StatusDate><Source id="734011" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-04-10T00:00:00.000Z</StatusDate><Source id="782327" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20348">Teva Pharmaceutical Industries Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="170">Huntingtons chorea</Indication><AwardedIndication>Treatment of Huntington's disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-04-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20348">Teva Pharmaceutical Industries Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="170">Huntingtons chorea</Indication><AwardedIndication>Treatment of Huntington's disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-07-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20348">Teva Pharmaceutical Industries Ltd</OwnerCompany><Country id="US">US</Country><Indication id="170">Huntingtons chorea</Indication><AwardedIndication>Treatment of Huntington's disease.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-12-12T00:00:00.000Z</MileStoneDate><Source id="679163" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20348">Teva Pharmaceutical Industries Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="170">Huntingtons chorea</Indication><AwardedIndication>Treatment of Huntington's disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-06-20T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20348">Teva Pharmaceutical Industries Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="170">Huntingtons chorea</Indication><AwardedIndication>Treatment of Huntington's disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-05-12T00:00:00.000Z</MileStoneDate><Source id="679164" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="GTGT-00228"><Name>BDNF gene</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-00633"><Name>Dopamine D2 receptor</Name><SwissprotNumbers><Swissprot>O73810</Swissprot><Swissprot>P14416</Swissprot><Swissprot>P20288</Swissprot><Swissprot>P52702</Swissprot><Swissprot>P60026</Swissprot><Swissprot>P61168</Swissprot><Swissprot>P61169</Swissprot><Swissprot>Q9GJU1</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01738"><Name>Opioid receptor sigma 1</Name><SwissprotNumbers><Swissprot>O55242</Swissprot><Swissprot>Q58DH7</Swissprot><Swissprot>Q5PXE2</Swissprot><Swissprot>Q5PXE3</Swissprot><Swissprot>Q5ZL84</Swissprot><Swissprot>Q60492</Swissprot><Swissprot>Q645J3</Swissprot><Swissprot>Q66IM1</Swissprot><Swissprot>Q6DCU6</Swissprot><Swissprot>Q7ZWG9</Swissprot><Swissprot>Q99720</Swissprot><Swissprot>Q9R0C9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2035016" linkType="reference" linkID="2035016"&gt;2035016&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18504">NeuroSearch A/S</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>3</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>2</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCCN1CCC(CC1)c2cccc(c2)S(=O)(=O)C.Cl</Smiles><Smiles>CCCN1CCC(CC1)c2cccc(c2)S(=O)(=O)C</Smiles></StructureSmiles><Deals><Deal id="107652" title="Fujisawa to develop Carlsson's ACR-16 for schizophrenia worldwide  "></Deal><Deal id="110879" title="Merck to develop Carlsson's ACR-16   "></Deal><Deal id="141896" title="Teva to acquire NeuroSearch's Huntexil for HD            "></Deal></Deals><PatentFamilies><PatentFamily id="1011508" number="WO-00146144" title="New modulators of dopamine neurotransmission"></PatentFamily><PatentFamily id="148443" number="US-20110206782" title="Piperidine modulators of dopamine receptor"></PatentFamily><PatentFamily id="2492045" number="WO-2013034622" title="Polymorphic form of pridopidine hydrochloride"></PatentFamily><PatentFamily id="2544720" number="WO-2013086425" title="The hydrobromide salt of pridopidine"></PatentFamily><PatentFamily id="2605505" number="WO-2013152105" title="Pharmaceutical compositions for combination therapy"></PatentFamily><PatentFamily id="2706849" number="WO-2014052935" title="Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease"></PatentFamily><PatentFamily id="2706852" number="WO-2014052933" title="Laquinimod and pridopidine for treating neurodegenerative disorders"></PatentFamily><PatentFamily id="2851308" number="WO-2014205229" title="Use of high dose pridopidine for treating Huntington's disease"></PatentFamily><PatentFamily id="2976517" number="WO-2015112601" title="Modified release formulations of pridopidine"></PatentFamily><PatentFamily id="3210158" number="WO-2016106142" title="L-tartrate salt of pridopidine"></PatentFamily><PatentFamily id="3318806" number="WO-2016138130" title="Use of pridopidine to improve cognitive function and for treating Alzheimer's disease"></PatentFamily><PatentFamily id="3318808" number="WO-2016138135" title="Sigma-1 receptor modulators for treating Huntington's disease"></PatentFamily><PatentFamily id="3475577" number="WO-2016003919" title="Analogs of pridopidine, their preparation and use"></PatentFamily><PatentFamily id="3523183" number="WO-2017015609" title="Process for preparing pridopidine"></PatentFamily><PatentFamily id="3523188" number="WO-2017015615" title="Pridopidine base formulations and their use"></PatentFamily><PatentFamily id="356516" number="WO-2008155357" title="Use of dopamine stabilizers"></PatentFamily><PatentFamily id="3576994" number="WO-2017048457" title="Combination of laquinimod and pridopidine to treat multiple sclerosis"></PatentFamily><PatentFamily id="3774269" number="WO-2017147366" title="Treatment of neurodegenerative eye disease using pridopidine"></PatentFamily><PatentFamily id="3964023" number="WO-2018039475" title="Use of pridopidine for treating dystonias"></PatentFamily><PatentFamily id="3988957" number="WO-2018053275" title="Use of pridopidine for the treatment of familial dysautonomia"></PatentFamily><PatentFamily id="3988959" number="WO-2018053280" title="Use of pridopidine for treating rett syndrome"></PatentFamily><PatentFamily id="3988962" number="WO-2018053287" title="Use of pridopidine for the treatment of anxiety and depression"></PatentFamily><PatentFamily id="4135610" number="WO-2018136600" title="Use of pridopidine for the treatment of fragile X syndrome"></PatentFamily><PatentFamily id="4146554" number="EP-03357909" title="Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine"></PatentFamily><PatentFamily id="4261426" number="WO-2018207192" title="Methods of treating leukodystrophies"></PatentFamily><PatentFamily id="4398082" number="WO-2019036358" title="Method of treating amyotrophic lateral sclerosis with pridopidine"></PatentFamily><PatentFamily id="4420140" number="WO-2019046568" title="High copncentration dosage forms of pridopidine"></PatentFamily><PatentFamily id="4429383" number="WO-2019050775" title="Pridopidine for treating drug induced dyskinesias"></PatentFamily><PatentFamily id="448061" number="WO-2012028635" title="Deuterated analogs of pridopidine useful as dopaminergic stabilizers"></PatentFamily><PatentFamily id="476929" number="WO-2006040155" title="Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine"></PatentFamily><PatentFamily id="671227" number="WO-2011107583" title="Substituted 4-phenyl-N-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders"></PatentFamily><PatentFamily id="911634" number="WO-09903470" title="Medicinal product and method for treatment and prevention of cognitive disorders."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>14</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>13</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pluristem Therapeutics Inc" id="1003864"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agency For Science Technology &amp; Research" id="1006569"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ivax International Bv" id="1059835"></CompanyLink><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National University Health System" id="1087042"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Prilenia Therapeutics Development Ltd" id="1182166"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NeuroSearch A/S" id="18504"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>26</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>26</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bar-Ilan University" id="20531"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tel Aviv University" id="25012"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>